We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
In This Issue of JAMA Ophthalmology |

Highlights FREE

JAMA Ophthalmol. 2014;132(11):1265. doi:10.1001/jamaophthalmol.2013.5968.
Text Size: A A A
Published online


Because payers and patients might benefit economically by switching from delayed sequential cataract surgery (DSCS) to immediate sequential cataract surgery (ISCS), Neel performs a cost-minimization analysis comparing ISCS with DSCS in the United States from the payer, patient, and societal perspectives for the West Tennessee region and nationally. Nationally, Medicare was estimated to reduce costs by approximately $522 million with the switch from DSCS to ISCS in 2012, with the total Medicare-based societal cost reduction estimated at $783 million. The author concludes that payers and patients might benefit from an economic standpoint by switching from DSCS to ISCS.

To pursue a visual field parameter that is resistant to cataract formation and extraction, which might help monitor glaucomatous visual field worsening in patients with coexisting glaucoma and cataract, Lee and colleagues retrospectively evaluate the influence of cataract surgery on the fast and slow rate components of visual field decay in 68 patients with glaucoma with 5 or more reliable visual fields both before and after surgery. The mean (SD) mean deviation was −5.5 (5.1) dB before and −5.0 (4.9) dB after cataract surgery (P = .002), while the mean (SD) Visual Field Index was 86.4% (13.5%) before and 86.6% (13.3%) after cataract surgery (P = .30). The authors concluded that worsening cataract seems to be the main determinant for the slow rate component and does not appear to change the fast rate component. Thus, this method might help reduce the confounding effects of worsening cataract and cataract extraction on worsening perimetry measurements in glaucoma.

With limited data regarding the systemic safety of intravitreal anti–vascular endothelial growth factor (VEGF) monoclonal antibody, Thulliez and colleagues conduct a systematic review and meta-analysis evaluating major cardiovascular risks and nonocular hemorrhagic events in patients with neovascular age-related macular degeneration, diabetes mellitus–associated macular edema, or retinal vein occlusions who receive these injections. Using a fixed-effects model among 21 trials that evaluated 9557 patients, the authors were not able to identify an increased risk for major cardiovascular events (odds ratio, 1.18; 95% CI, 0.81-1.71) or nonocular hemorrhagic events (odds ratio, 1.42; 95% CI, 0.95-2.13) compared with control populations, although bevacizumab compared with ranibizumab had increased venous thromboembolic events (odds ratio, 3.45; 95% CI, 1.25-9.54). The authors stated that studies and meta-analyses were not powered enough to assess these risks confidently, that these results should be interpreted with caution, and that more safety data are needed.

Recognizing that children born prematurely who develop retinopathy of prematurity (ROP) often develop myopia and that those who require laser treatment may develop very high myopia, with considerable clinical consequences, Geloneck and colleagues report refractive outcomes from among the 150 preterm infants who developed ROP in zone I or zone II posterior as stage 3+ ROP or aggressive posterior ROP in a multicenter randomized clinical trial. Among the 109 children who received intravitreal bevacizumab or laser in the clinical trial for whom cycloplegic retinoscopic refraction at a mean age of 2.5 years was available, very high myopia (≥−8.00 D myopic) occurred in zone I in 2 of 52 eyes (3.8%) that received intravitreal bevacizumab compared with 18 of 35 eyes (51.4%) that received laser treatment (P < .001). The authors hypothesized that this difference possibly is related to anterior segment development that is present with intravitreal bevacizumab but minimal or absent following laser treatment.





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Related Content

Customize your page view by dragging & repositioning the boxes below.